

Lumito's main owner, CEO and a member of the board exercise their subscription warrants in full

During the first exercise window, Lumito's major shareholder, Cardeon Futuring Finance (40 percent of which is owned by Masoud Khayyami), Lumito's CEO, Stefan Nilsson, and member of the board Ulf Bladin have exercised all of their Series TO2 warrants to subscribe for shares in Lumito AB. In total, this amounts to 2,130,000 subscription warrants.

After the exercise of warrants, Stefan Nilsson's holding amounts to 1,314,643 shares, privately and via companies. Cardeon Futuring Finance's holding amounts to 5,000,000 shares in total, privately and via companies, after the exercise of warrants.

Ulf Bladin has subscribed in full with his TO2, and now holds 120,000 shares.

According to the Series TO2 warrant conditions, two (2) warrants entitles to subscription of one (1) new share, at a subscription price of SEK 1.45 per share, during the first exercise window (1 November to 29 November 2019 inclusive). The second exercise window is open between 1 May 2020 and 30 May 2020. During this period, two (2) Series TO2 warrants entitles to subscription of one (1) new share at a subscription price of SEK 1.55 per share.

For more information contact:

Lumito AB (publ), CEO Stefan Nilsson, telefon +46 767 78 59 05, sn@lumito.se

Lumito

Lumito is specialised in research and development of imaging technologies for medical applications. The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications. Lumito's IPR covers, with UCNP:s as markers, imaging with high quality of for instance tissue samples. The technology has several possible application areas and Lumito has firstly focused on digital pathology. Lumito has an agreement regarding development of instrument and staining kits with TTP plc (The Technology Partnership) in Cambridge UK. Lumito shares LUMITO MTF and warrants LUMITO MTF TO1 are traded at the marketplace NGM Nordic MTF.